Rukobia
Payments companies reported to CMS as associated with Rukobia. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rukobia, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rukobia
These are the largest totals companies reported as associated with Rukobia. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Michael Sension | Fort Lauderdale, FL | Internal Medicine | $275,510.69 |
| Karam Mounzer | Philadelphia, PA | Infectious Disease | $96,596.73 |
| Brian Beesley | Columbus, OH | Family Medicine | $93,908.54 |
| Elizabeth Race | Dallas, TX | Infectious Disease | $88,784.23 |
| Ricky Hsu | New York, NY | Internal Medicine | $59,994.12 |
| Charlotte-Paige Rolle | Orlando, FL | Infectious Disease | $53,233.57 |
| Douglas Cunningham | Phoenix, AZ | Family Medicine | $50,537.00 |
| Louis Cubba | San Francisco, CA | Internal Medicine | $44,195.55 |
| Jihad Slim | Newark, NJ | Infectious Disease | $39,906.88 |
| Bisher Akil | New York, NY | Pulmonary Disease | $36,640.34 |
Prescribed Rukobia?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.